Search | Clinical Trials Finder

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Healthy Adult Subjects
Interventions: Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Stress Disorder, Anxiety, Pain
Interventions: Intranasal Dexmedetomidine (4 mcg/kg), Intranasal Fentanyl (2 mcg/kg), Intranasal Midazolam (5 mg/kg); Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 2 Years to 6 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Interventions: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block, 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block, Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed, 45-60 mg of 1.5% mepivacaine for spinal anesthesia, LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Anxiety, Nausea
Interventions: Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more

Conditions: Drug Interactions
Interventions: CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Schizophrenia Patients
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Culver City, California

Conditions: Crohn's Disease
Interventions: GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Postoperative Pain
Interventions: Epidural Analgesia, Patient-Controlled IV Analgesia; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Total Knee Replacement, Genicular Nerve Block, Opioid Use
Interventions: Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
Interventions: Randomized Midazolam, Placebo, Local Anesthesia, Prospective Midazolam; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bronchoscopy
Interventions: Remifentanil, Fentanyl, Midazolam, Ketamine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Postoperative Pain, Hip Arthroscopy
Interventions: Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline; Procedure · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Seizures
Interventions: Midazolam; Drug
Lead sponsor: U.S. Army Office of the Surgeon General; Federal
Eligibility: 18 Years to 54 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Laparoscopic Colorectal Resection
Interventions: TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Lanabecestat, Simvastatin, Midazolam, Donepezil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Procedural Anxiety
Interventions: Intranasal midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 7 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Interaction Drug Food
Interventions: Midazolam HCl, Dextromethorphan HBr, Kratom; Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Atherosclerosis
Interventions: Darapladib, Midazolam; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: nasal Midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room

Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.

Evaluation of Oral Midazolam in First-trimester Surgical Abortions

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

Pain Management for Pectus Excavatum Repair

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

Shaping Anesthetic Techniques to Reduce Post-operative Delirium

Drug-drug Interaction Study of Gepotidacin

PENG Block for Arthroscopic Hip Surgery

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG